Vast Therapeutics
  • Home
  • About
    • Company Overview
    • Our Team
    • Scientific Advisory Board
    • Careers
  • Technology
    • Nitric Oxide
    • Need for Antibiotic Alternatives
    • Broad Spectrum Efficacy
  • Applications
    • Cystic Fibrosis
    • NTM Lung Disease
    • Other Targets
  • Media
  • Investors

Media

​Novoclem announces CEO Anne Whitaker to present at the Biotech Showcase™ Annual Conference on ​Wednesday, January 10, 2018

1/4/2018

 
​Novoclem announces CEO Anne Whitaker to present at the Biotech Showcase™ Annual Conference on
​Wednesday, January 10, 2018

DURHAM, NC ( Jan. 4, 2018) – Novoclem Therapeutics, a preclinical-stage pharmaceutical company focused on helping people who suffer from severe respiratory diseases to breathe better and live life more fully, today announced that it will present at Biotech Showcase™ 2018, to be held January 8th –10th at the Hilton San Francisco Union Square.

About Biotech Showcase 2018

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

About Novoclem Therapeutics, Inc.

Novoclem Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, is initially focused on developing a nitric oxide based treatment for people living with cystic fibrosis and infected with Pseudomonas aeruginosa. The company anticipates submitting an Investigational New Drug application and initiating First in Human clinical trials in 2018. More info available at vasttherapeutics.com.

About KNOW Bio LLC

KNOW Bio, LLC, is a life science company committed to improving and extending people’s lives by advancing the development and commercialization of its drug and device pipeline through wholly or majority owned subsidiary companies. Each subsidiary is focused on a specific therapeutic application where nitric oxide provides meaningful health benefit.

Forward-looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: risks associated with the drug development process; reliance on key personnel; the early stage of our business; competition; and other risks described in other Company press releases and presentations. KNOW Bio and Novoclem Therapeutics assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Media Contact:
​

Darlene Dendy
1-919-270-5789
ddendy@novoclem.com


Comments are closed.


    Archives

    January 2021
    September 2020
    October 2019
    May 2019
    January 2019
    December 2018
    May 2018
    February 2018
    January 2018
    November 2017
    October 2017
    July 2017
    April 2017
    January 2017


    ​Categories

    All
    Anthrax
    BIOC11
    BIOC51
    Biotech Showcase
    CED
    CFF
    Conference
    COVID-19
    Cystic Fibrosis
    Funding
    GAIN Act
    NACFC
    NCBIO
    News Article
    Nitric Oxide
    NTM Animal Model
    Partnership
    Patent
    Pathogens
    Press Release
    QIDP Status
    SARS-CoV-2
    Superbugs
    Therapy
    Video

    RSS Feed

Vast Therapeutics logo - white

Address

​4222 Emperor Blvd. Suite 470
​Durham, NC 27703

Contact Us

info@vasttherapeutics.com

Sector

Biopharmaceutical

Industry

​Biotechnology

    Sign Up for Email Alerts

Submit
​Forward-Looking Statement | Privacy | Terms of Use | Site Map
​Copyright © 2021 Vast Therapeutics - All Rights Reserved
Picture
  • Home
  • About
    • Company Overview
    • Our Team
    • Scientific Advisory Board
    • Careers
  • Technology
    • Nitric Oxide
    • Need for Antibiotic Alternatives
    • Broad Spectrum Efficacy
  • Applications
    • Cystic Fibrosis
    • NTM Lung Disease
    • Other Targets
  • Media
  • Investors